Damora Therapeutics, Inc.
- DMRA
- NASDAQ
- Biotechnology
- Cancer/Fibrosis Drugs
- Small Molecule Therapeutics
$18.44
Today −1.60%Quote Oct 16, 2026, 08:00 PM UTC
−19.05%over the last month
Max drawdown −19.3%From 1-month high −19.3%3 months −44.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.14B
Quote Oct 16
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$50.00
+171.1% from here
Floor
$18.20
1.3% below price
Where the price sits
3 analysts
Analyst range, low to high
$40.00$60.00
- Price $18.44
- Resistance $18.90
- Consensus $50.00
The price is just above its floor and right under resistance. Analysts' average target sits about 171% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about DMRAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
7
Founded
2011